Immunic Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Immunic is gedaald met een gemiddeld jaarlijks tempo van -25.2%, terwijl de winst van de sector Biotechs jaarlijks groeide met 19.1%.

Belangrijke informatie

-25.2%

Groei van de winst

19.5%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	n/a
Rendement op eigen vermogen	-149.9%
Nettomarge	n/a
Volgende winstupdate	07 Nov 2024

Recente prestatie-updates uit het verleden

Recent updates

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Oct 25

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Jan 22

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Oct 13

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

Jun 27

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Oct 20

Opbrengsten en kosten

Hoe Immunic geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:IMUX Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	-95	18	76
31 Mar 24	-98	17	79
31 Dec 23	-94	16	83
30 Sep 23	-129	16	85
30 Jun 23	-127	15	81
31 Mar 23	-125	16	77
31 Dec 22	-120	15	71
30 Sep 22	-85	15	69
30 Jun 22	-83	14	68
31 Mar 22	-79	14	67
31 Dec 21	-93	13	61
30 Sep 21	-83	13	54
30 Jun 21	-77	13	49
31 Mar 21	-70	11	44
31 Dec 20	-44	10	39
30 Sep 20	-41	18	33
30 Jun 20	-36	18	30
31 Mar 20	-39	16	26
31 Dec 19	-35	15	23
30 Sep 19	-32	5	21
30 Jun 19	-26	3	15
31 Mar 19	-14	3	11
31 Dec 18	-12	2	10
30 Sep 18	-10	2	9
31 Dec 17	-10	1	9
31 Dec 16	-1	1	1

Kwaliteitswinsten: IMUX is momenteel verliesgevend.

Groeiende winstmarge: IMUX is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: IMUX is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 25.2% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van IMUX over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: IMUX is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( -2.3% ).

Rendement op eigen vermogen

Hoge ROE: IMUX heeft een negatief Return on Equity ( -149.91% ), omdat het momenteel verliesgevend is.

Immunic Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Immunic, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Immunic, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Immunic, Inc. to Report Q1, 2024 Results on May 08, 2024

Immunic, Inc. to Report Fiscal Year 2023 Results on Feb 22, 2024

Immunic, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Immunic, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Recent updates

Immunic, Inc. to Report Q3, 2024 Results on Nov 07, 2024

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Immunic, Inc. Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial ofidofludimus Calcium in Patients with Post COVID Syndrome

Price target decreased by 13% to US$11.90

New major risk - Financial position

New minor risk - Share price stability

New minor risk - Profitability

No longer forecast to breakeven

New major risk - Financial position

Immunic, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Immunic, Inc. Appoints Simona Skerjanec as Member of the Board

Immunic, Inc. Appoints Jason Tardio as Chief Operating Officer and President

New minor risk - Profitability

No longer forecast to breakeven

Immunic, Inc. to Report Q1, 2024 Results on May 08, 2024

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Immunic, Inc., Annual General Meeting, Jun 11, 2024

Price target decreased by 32% to US$9.00

Immunic, Inc. to Report Fiscal Year 2023 Results on Feb 22, 2024

New major risk - Shareholder dilution

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Immunic, Inc. announced that it expects to receive $240 million in funding from BVF Partners L.P., Avidity Partners, LLC, Janus Henderson Investors, Soleus Capital, RTW Investments, LP, Adage Capital Management, L.P.

Forecast to breakeven in 2026

New major risk - Financial position

Immunic, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis Vidofludimus and Its Salts

Immunic, Inc. Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Immunic Reports Positive Interim Data from Phase 2 Calliper Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Immunic, Inc. Completes Enrollment of Its Phase 2 CallIPER Trial ofidofludimus Calcium in Progressive Multiple Sclerosis

New major risk - Share price stability

Immunic, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

Immunic, Inc. to Report Q1, 2023 Results on May 11, 2023

Immunic, Inc. Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

High number of new directors

Price target decreased by 15% to US$18.00

Immunic, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Independent Director recently bought US$103k worth of stock

Immunic, Inc Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

High number of new directors

Price target decreased to US$21.17

Price target decreased to US$21.17

Immunic, Inc. Provides Impairment Guidance for the Quarter Ending December 31, 2022

Immunic, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Price target increased to US$28.75

Immunic, Inc. Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Immunic, Inc. announced that it expects to receive $59.949037 million in funding from a group of investors

Immunic stock gains on $60M oversubscribed PIPE financing

Immunic, Inc Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects

Immunic, Inc. Receives Notice of Allowance for Composition-Of-Matter Patent in the United States for IMU-856, A Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium

Price target decreased to US$22.40

Immunic GAAP EPS of -$0.72 in-line

Immunic, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Immunic, Inc. Announces Executive Changes

Immunic, Inc.(NasdaqGS:IMUX) dropped from Russell 2000 Dynamic Index

Immunic, Inc. Announces Publication of Data From its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology

Immunic, Inc. Reports Top-Line Data from Phase 2 Caldose-1 Trial of Vidofludimus Calcium in Patients with Moderate-To-Severe Ulcerative Colitis

Price target decreased to US$49.43

Executive Chairman recently bought US$50k worth of stock

Immunic, Inc. Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

Immunic, Inc. to Report Q1, 2022 Results on May 10, 2022

High number of new directors

Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis

Immunic, Inc. to Report Fiscal Year 2021 Results on Feb 24, 2022